Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Enveric Biosciences, Inc. - Common Stock (NQ:ENVB)

1.340 -0.010 (-0.75%)
Streaming Delayed Price Updated: 11:11 AM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Enveric Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Enveric Biosciences Expands IP Portfolio with New U.S. Patent for Novel Carboxylated Psilocybin Derivatives Supporting its EVM301 Series of Drug Candidates
From Enveric Biosciences
Via Business Wire
Enveric Biosciences to Present Poster Highlighting EVM301 Series at the International Conference on Molecular Biology and Biochemistry 2023
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Files Provisional Patent Application for AI-based Computational Methods for Identifying and Optimizing Novel Tryptamine Derivatives
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Inc. (NASDAQ: ENVB) Leading the Way in Wednesday Trading Based on Percentage Gain
Via Investor Brand Network
Enveric Biosciences Announces New U.S. Patent for C4-Carboxylic Acid-Substituted Tryptamine Derivatives
From Enveric Biosciences
Via Business Wire
Enveric Biosciences to Present at H.C. Wainwright 25th Annual Global Conference
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Strengthens Intellectual Property Portfolio with New U.S. Patent for Tryptamine-derived Prodrugs
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Completes Manufacturing of EB-373 to Supply Drug Material for Completion of Preclinical Program
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Reports Second Quarter 2023 Corporate and Financial Results
From Enveric Biosciences, Inc.
Via Business Wire
Enveric Biosciences Reports Positive Results from Preclinical Studies Supporting Metabolic Profile of Lead Candidate EB-373
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Reports Positive Results from Animal Studies Demonstrating Oral Bioavailability and Well Tolerated Side Effect Profile for EB-373
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Announces Development of Phase 1-Ready Formulation for EB-373 and Initiation of Scaled Up Manufacturing
From Enveric Biosciences
Via Business Wire
Enveric Biosciences to Present at H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Announces Two Poster Presentations at the Canadian Chemistry Conference and Exhibition (CSC 2023)
From Enveric Biosciences, Inc.
Via Business Wire
Enveric Biosciences Receives Notice of Allowance from USPTO for EVM301 Series of Drug Candidates
From Enveric Biosciences, Inc.
Via Business Wire
Enveric Biosciences Announces Poster Presentation at Canadian Neuroscience Meeting 2023
From Enveric Biosciences, Inc.
Via Business Wire
Enveric Biosciences Receives Notice of Allowance From USPTO for C4-Carboxylic Acid-Substituted Tryptamine Derivatives for Next Generation Psilocin Prodrug
From Enveric Biosciences, Inc.
Via Business Wire
Enveric Biosciences Announces Manuscript Detailing the Development of Novel Psilocin Prodrugs for the Treatment of Anxiety and Other Mental Health Disorders
From Enveric Biosciences, Inc.
Via Business Wire
Enveric Biosciences to Participate in 2023 BIO International Convention in Boston
From Enveric Biosciences, Inc.
Via Business Wire
Enveric Biosciences Inc. (NASDAQ: ENVB) is One of Thursday Morning’s Most Active Stocks
Via Investor Brand Network
Enveric Biosciences (NASDAQ: ENVB) Obtains Notice of Allowance For a U.S. Patent Covering Its Innovative Psilocin Prodrug, EB-373
Enveric Biosciences, Inc. (NASDAQ: ENVB) is engaged as a biotechnology company, which focused on the research and development of innovative 
Via Spotlight Growth
Topics Derivatives Intellectual Property
Enveric Biosciences Receives Notice of Allowance from USPTO for Novel Prodrug of Psilocin
From Enveric Biosciences, Inc.
Via Business Wire
Enveric Biosciences Reports First Quarter 2023 Financial Results and Operational Highlights
From Enveric Biosciences, Inc.
Via Business Wire
Enveric Biosciences Celebrates and Supports 2023 Mental Health Awareness Month
From Enveric Biosciences, Inc.
Via Business Wire
Enveric Biosciences to Participate in Benzinga Psychedelics Capital Conference
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Reports Fourth Quarter and Year-End 2022 Corporate and Financial Results
From Enveric Biosciences, Inc.
Via Business Wire
Enveric Biosciences Selects Australian CRO, Avance Clinical, in Preparation for Phase 1 Study of EB-373
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Establishes Australia-based Subsidiary to Accelerate its Lead Psilocin Prodrug Program Targeting Mental Health Indications
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Announces Bioproduction Platform Using Novel Cane Toad Enzyme for Psychedelic-Inspired Drug Discovery
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Appoints Kevin Coveney as Chief Financial Officer, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Enveric Biosciences
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.